Sagimet Biosciences
SGMT
81 hedge funds and large institutions have $122M invested in Sagimet Biosciences in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 31 increasing their positions, 11 reducing their positions, and 5 closing their positions.
600% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 5
182% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 11
61% more capital invested
Capital invested by funds: $76.2M → $122M (+$46.2M)
59% more funds holding
Funds holding: 51 → 81 (+30)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38.13% more ownership
Funds ownership: 67.62% → 105.75% (+38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.2M |
| 2 |
BlackRock
New York
|
+$11.8M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$9.47M |
| 4 |
JP Morgan Chase
New York
|
+$8.04M |
| 5 |
RI
RTW Investments
New York
|
+$7.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$13.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.9M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$5.2M |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.53M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.44M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
76
Ameritas Investment Partners
Lincoln,
Nebraska
| $2.85K | – | – | – |
|
|
HGERS
77
Householder Group Estate & Retirement Specialist
Scottsdale,
Arizona
| $2.58K | +$3.43K | +477 | New |
|
|
AB
78
Amalgamated Bank
New York
| $1K | -$2.47K | -344 | -65% |
|
|
TFA
79
Toth Financial Advisory
Leesburg,
Virginia
| $488 | +$646 | +90 | New |
|
|
FIA
80
FNY Investment Advisers
New York
| $181 | +$241K | +33,500 | New |
|
81
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $92 | +$122 | +17 | New |
|
|
ACM
82
Altium Capital Management
New York
| – | -$2.53M | -483,181 | Closed |
|
|
GCM
83
Ghisallo Capital Management
Boston,
Massachusetts
| – | -$325K | -60,000 | Closed |
|
|
VF
84
Virtu Financial
New York
| – | -$67K | -12,301 | Closed |
|
|
SIM
85
Sandia Investment Management
Boston,
Massachusetts
| – | -$32.4K | -5,986 | Closed |
|
86
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$6.76K | -1,247 | Closed |
|
SGMT Hedge Fund Activity: Q1 2024 in Review
81 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q1 2024, worth a combined $122M — up 61% from $76.2M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new SGMT positions and 5 closed out — a net gain of 30 holders — while 31 added to existing stakes and 11 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $19.2M. The largest seller was NEA Management Company, cutting an estimated $13.3M.
- 81 institutional investors held Sagimet Biosciences (SGMT) as of Q1 2024, up from 51 in Q4 2023.
- Funds reported $122M of Sagimet Biosciences stock for Q1 2024, up 61% quarter-over-quarter.
- 35 funds opened new Sagimet Biosciences positions in Q1 2024 and 5 closed out, a net change of +30 holders.
- The largest Sagimet Biosciences buyer in Q1 2024 was Point72 Asset Management, an estimated $19.2M added.
- The largest Sagimet Biosciences seller in Q1 2024 was NEA Management Company, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2024.